測定可能病変を有していない進行再発胃癌を対象としたS-1+DTX 療法とS-1+CDDP 療法のランダム化第Ⅱ相試験(HERBIS-3 / OGSG1104)

A phase II trial of perioperative CapeOx for clinical stage III gastric cancer (OGSG1601)

Trastuzumab With S-1 Plus Cisplatin in HER2-positive Advanced Gastric Cancer Without Measurable Lesions: OGSG 1202

Randomized, Open-Label Phase II Study Comparing Capecitabine- Cisplatin Every 3 Weeks with S-1-Cisplatin Every 5 Weeks in Chemotherapy-Naïve Patients with HER2-Negative Advanced Gastric Cancer: OGSG1105, HERBIS-4A Trial

Randomized phase II study to compare docetaxel plus S-1 with cisplatin plus S-1 in advanced gastric cancer without measurable lesions (HERBIS-3)

Randomized, open-label, phase II study comparing five-weekly S-1 plus cisplatin (SP) with triweekly capecitabine plus cisplatin (XP) in chemotherapy-naïve patients with HER2 negative advanced gastric cancer (AGC) (HERBIS-4A / OGSG 1105)

A phase II study to examine the effectiveness of nutritional support with elemental diet for stage II/III gastric cancer patients receiving adjuvant chemotherapy with S-1 (OGSG 1108)

測定可能病変を有していない進行再発胃癌を対象としたS-1+DTX 療法とS-1+CDDP 療法のランダム化第Ⅱ相試験(HERBIS-3)

S-1による胃癌術後補助化学療法患者に対する成分栄養剤(エレンタールⓇ)の有用性に関する第II相臨床試験 (OGSG1108)

Phase II study to examine the efficacy of Oral elemental diet in gastric cancer patients for adjuvant chemotherapy (OGSG 1108)